A Phase III study to evaluate the safety and efficacy of intravitreal (IVT) injections of conbercept versus aflibercept in subjects with neovascular (wet) age-related macular degeneration (wAMD).

Both conbercept and aflibercept inhibit a protein (VEGF) that promotes the growth of the abnormal blood vessels characteristic of wAMD. Aflibercept is the active ingredient in Eylea, a drug that has already received market approval. Conbercept is thought to bind more specifically to VEGF, reducing the dosage required, and also has a longer half-life than other available treatments.

• Subjects age ≥ 50 years
• 1140 subjects total
• Study duration: 92 weeks
• Recruiting subjects who have never received treatment for wAMD

Those that qualify may receive study-related care from a board-certified physician at no cost, receive compensation for time and travel, and have access to potential new medication.

Contact Retina Associates at 630.571.1501 or kjager@retinaassociates.com to learn more about Retina Research.

Visit our Patient Resources page to learn how we help.